ESTRO 2023 - Abstract Book

S871

Digital Posters

ESTRO 2023

Care plans dedicated to breast cancer treatments have been reviewed over the period of time 2008 to now. Radiation treatments as: whole breast irradiation (WBI), partial breast irradiation (PBI) or loco-regional irradiation, fractionation prescribed and time from ready-to-treat to start date have been computed per year. Results Numbers of breast cancers treated yearly by radiotherapy has increased from 602 in 2008 up to 917 in 2021. The number of linacs did not increase over that period, nor did the number of breast radiation oncologists. Since 2017 (7 years after the 10 years follow-up publication of the hypofractionated Canadian trial), all whole breast irradiations are prescribed the 3 weeks regimen. In 2020, with COVID19 and UK forward and fast-forward trials published, 5 fractions started to be prescribed for 10% of treatments, but that number increased to 38% over the first 9 months of 2022 (up to now, a total of 297 patients treated WBI 5 fractions, average age 74y +/- 8y). PBI 3 weeks started to be prescribed in 2018 but was replaced by Accelerated PBI 5 fractions in 2020 and in 2022 is representing 15% of all breast-only radiation treatments (up to now a total of 128 patients treated APBI, average age 68y +/- 8y) For Loco-regional treatments: 3 weeks regimen was used for 60% of patients in 2019 but jumped to 85% in 2020 and since 2021 is the standard of care. Considering the radiation treatment prescriptions we have used in 2019, the fractionation prescription changes seen since mid-2020 and until Sept 2022 have freed up from linacs a total of around 6000 breast sessions. Since 2018, the time from ready-to-treat to radiation-start date has stayed stable with an average of 11 days Conclusion The COVID19 pandemic combined with the UK trials publication has facilitated the adoption of APBI 5 fractions. WBI using 5 fractions is now used in 38% of patients, aged around 74y old. Three weeks regimen is now the standard of care for loco regional treatments. These fractionation changes may have facilitated keeping waiting time for treatment low, in a challenging time. M. Koeksal 1 , R. Streppel 1 , C. Schmeel 2 , A. Mustea 3 , S. Hauser 4 , M. Ritter 4 , A. Abramian 5 , A. Faridi 6 , M. Gonzalez-Carmona 7 , P. Brossart 7 , N. Schäfer 8 , U. Herrlinger 8 , M. Banat 9 , E. Güresir 9 , H. Vatter 9 , U. Höller 10 , F. Giordano 11 1 University Medical Center, Radiation oncology, Bonn, Germany; 2 University Medical Center, Radiatoin Oncology, Bonn, Germany; 3 University Medical Center, Gynaecology and Gynaecological Oncology, Bonn, Germany; 4 University Medical Center, Urology, Bonn, Germany; 5 University Medical Center, Senology and Breast Center, Bonn, Germany; 6 University Medical Center, Senology and Breast Cancer, Bonn, Germany; 7 University Medical Center, Internal Medicine, Bonn, Germany; 8 University Medical Center, Neuro-Oncology, Bonn, Germany; 9 University Medical Center, Neurosurgery, Bonn, Germany; 10 German Society for Radiation Oncology , DEGRO, Berlin, Germany; 11 University Medical Center, Radiation oncology , Bonn, Germany Purpose or Objective The concept of personalized medicine (PM) aims at unique and tailored prevention, diagnosis, and treatment for individual groups of people. To accomplish this, factors predicting and diagnosing certain unfavorable side effects must be revealed and adopt into clinical medicine. Literature suggests an association between health and various sociodemographic parameters, such as nationality. To our knowledge, no investigation has examined the association between nationality and early side effects (SEs) of radiotherapy in Germany. Materials and Methods Initially, 9,187 patients treated at our university between 2017 and 2021 were considered for investigation. A matched-pair analysis was conducted by matching 178 German patients to 178 non-German (hereinafter described as “foreign”) patients based on diagnostic and demographic criteria. For all 356 patients, well-documented data on SE from follow-up care after radiotherapy were collected. Results Our finding showed a difference in the quality, but not the quantity, of SE such that foreign patients display more severe early SEs compared to German patients. Furthermore, tumor entity, concurrent therapy, and body mass index were associated with SE severity. Conclusion In summary, our finding showed that foreign patients receiving radiotherapy were at high risk for more severe early SE, suggesting a great need to develop and implement targeted preventive measures for foreigners with cancer. Given the ongoing progress of PM, further research investigating predictive factors for SE is needed for better customization and individualization of interventions. Poster (Digital): Health economics / health services research PO-1088 Impact of nationality on the quality of early side effects following radiotherapy in Germany

PO-1089 Days and Gray: The cost of cyber-crime in Radiation Oncology

R. Joyce 1 , C. Lyons 1 , K. Rock 1 , F. Jamaluddin 1 , A. Flavin 1 , M. Hickey 2 , E. Bennett 2 , P. Kelly 2 , C. McGibney 1

1 Cork University Hospital, Radiation Oncology, Cork, Ireland; 2 UPMC Bons Secours, Radiation Oncology, Cork, Ireland

Purpose or Objective